VEGFR Inhibitor-Resistant Thyroid Cancer Responds to Cabozantinib [Clinical Trials]

Cabozantinib achieved partial responses in 40% of patients with differentiated thyroid cancer (DTC).

Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research